Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
PRT-2527 by Prelude Therapeutics for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval
PRT-2527 is under clinical development by Prelude Therapeutics and currently in Phase I for Human Epidermal Growth Factor Receptor 2...
PRT-2527 by Prelude Therapeutics for Non-Small Cell Lung Cancer: Likelihood of Approval
PRT-2527 is under clinical development by Prelude Therapeutics and currently in Phase I for Non-Small Cell Lung Cancer. According to...
PRT-2527 by Prelude Therapeutics for Solid Tumor: Likelihood of Approval
PRT-2527 is under clinical development by Prelude Therapeutics and currently in Phase I for Solid Tumor. According to GlobalData, Phase...
PRT-2527 by Prelude Therapeutics for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia): Likelihood of Approval
PRT-2527 is under clinical development by Prelude Therapeutics and currently in Phase I for Acute Myelocytic Leukemia (AML, Acute Myeloblastic...
PRT-2527 by Prelude Therapeutics for Sarcomas: Likelihood of Approval
PRT-2527 is under clinical development by Prelude Therapeutics and currently in Phase I for Sarcomas. According to GlobalData, Phase I...
PRT-3645 by Prelude Therapeutics for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval
PRT-3645 is under clinical development by Prelude Therapeutics and currently in Phase I for Human Epidermal Growth Factor Receptor 2...
PRT-3645 by Prelude Therapeutics for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval
PRT-3645 is under clinical development by Prelude Therapeutics and currently in Phase I for Head And Neck Squamous Cell Carcinoma...
PRT-3645 by Prelude Therapeutics for Recurrent Glioblastoma Multiforme (GBM): Likelihood of Approval
PRT-3645 is under clinical development by Prelude Therapeutics and currently in Phase I for Recurrent Glioblastoma Multiforme (GBM). According to...
PRT-3645 by Prelude Therapeutics for Oral Cavity (Mouth) Cancer: Likelihood of Approval
PRT-3645 is under clinical development by Prelude Therapeutics and currently in Phase I for Oral Cavity (Mouth) Cancer. According to...
PRT-3645 by Prelude Therapeutics for Oropharyngeal Cancer: Likelihood of Approval
PRT-3645 is under clinical development by Prelude Therapeutics and currently in Phase I for Oropharyngeal Cancer. According to GlobalData, Phase...
PRT-3645 by Prelude Therapeutics for Hypopharyngeal Cancer: Likelihood of Approval
PRT-3645 is under clinical development by Prelude Therapeutics and currently in Phase I for Hypopharyngeal Cancer. According to GlobalData, Phase...
PRT-3645 by Prelude Therapeutics for Laryngeal Cancer: Likelihood of Approval
PRT-3645 is under clinical development by Prelude Therapeutics and currently in Phase I for Laryngeal Cancer. According to GlobalData, Phase...
PRT-3645 by Prelude Therapeutics for Non-Small Cell Lung Cancer: Likelihood of Approval
PRT-3645 is under clinical development by Prelude Therapeutics and currently in Phase I for Non-Small Cell Lung Cancer. According to...
PRT-3645 by Prelude Therapeutics for Malignant Mesothelioma: Likelihood of Approval
PRT-3645 is under clinical development by Prelude Therapeutics and currently in Phase I for Malignant Mesothelioma. According to GlobalData, Phase...
PRT-3645 by Prelude Therapeutics for Endometrial Cancer: Likelihood of Approval
PRT-3645 is under clinical development by Prelude Therapeutics and currently in Phase I for Endometrial Cancer. According to GlobalData, Phase...
PRT-3645 by Prelude Therapeutics for Astrocytoma: Likelihood of Approval
PRT-3645 is under clinical development by Prelude Therapeutics and currently in Phase I for Astrocytoma. According to GlobalData, Phase I...
PRT-3645 by Prelude Therapeutics for Sarcomas: Likelihood of Approval
PRT-3645 is under clinical development by Prelude Therapeutics and currently in Phase I for Sarcomas. According to GlobalData, Phase I...
PRT-3645 by Prelude Therapeutics for Solid Tumor: Likelihood of Approval
PRT-3645 is under clinical development by Prelude Therapeutics and currently in Phase I for Solid Tumor. According to GlobalData, Phase...
PRT-3789 by Prelude Therapeutics for Non-Small Cell Lung Cancer: Likelihood of Approval
PRT-3789 is under clinical development by Prelude Therapeutics and currently in Phase I for Non-Small Cell Lung Cancer. According to...
PRT-3789 by Prelude Therapeutics for Solid Tumor: Likelihood of Approval
PRT-3789 is under clinical development by Prelude Therapeutics and currently in Phase I for Solid Tumor. According to GlobalData, Phase...